Immune surveillance in the skin: Mechanisms and clinical consequences

Nature Reviews Immunology

Volumn 4, Issue 3, 2004, Pages 211-222

  Kupper, Thomas S ^a   Fuhlbrigge, Robert C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR VACCINE;

ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; CUTANEOUS T CELL LYMPHOMA; EPITHELIUM CELL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST RESISTANCE; HUMAN; IMMUNITY; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN; SKIN ALLERGY; SKIN INFLAMMATION; SKIN TUMOR; T LYMPHOCYTE; VACCINE PRODUCTION; VITILIGO;

EID: 1542615639     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1310     Document Type: Review

References (162)

1. Robert, C. & Kupper, T. S. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med. 341, 1817-1828 (1999).
2. Uthayakumar, S., Nandwani, R., Drinkwater, T., Nayagarn, A. T. & Darley, C. R. The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br. J. Dermatol. 137, 595-598 (1997).
3. Lugo-Janer, G., Sánchez, J. L. & Santiago-Delpin, E. Prevalence and clinical spectrum of skin diseases in kidney transplant recipients. J. Am. Acad. Dermatol. 24, 410-414 (1991).
4. Kadunce, D. P. & Krueger, G. G. Pathogenesis of psoriasis. Dermatol. Clin. 13, 723-737 (1995).
5. Leung, D. Y. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin. Exp. Immunol. 107 Suppl. 1, 25-30 (1997).
6. Galli, E. et al. Atopic dermatitis: molecular mechanisms, clinical aspects and new therapeutical approaches. Curr. Mol. Med. 3, 127-138 (2003).
7. González, F. J. et al. Participation of T lymphocytes in cutaneous allergic reactions to drugs. Clin. Exp. Allergy 28 Suppl. 4, 3-6 (1998).
8. Porter, S. R., Kirby, A., Olsen, I. & Barrett, W. Immunologic aspects of dermal and oral lichen planus: a review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 83, 358-366 (1997).
9. McDonagh, A. J. & Messenger, A. G. The pathogenesis of alopecia areata. Dermatol. Clin. 14, 661-670 (1996).
10. Boh, E. E. & Millikan, L. E. Vesiculobullous diseases with prominent immunologic features. JAMA 268, 2893-2898 (1992).
11. Wong, E., Camp, R. D. R. & Greaves, M. W. The responses of normal and psoriatic skin to single and multiple topical applications of leukotriene B4. J. Invest. Dermatol. 84, 421-423 (1985).
12. Krueger, J. G., Wolfe, J. T. & Nabeya, R. T. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J. Exp. Med. 182, 2057-2068 (1995).
13. Gottlieb, S. L., Gilleaudeau, P. & Johnson, R. Response of psoriasis to be lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1, 442-447 (1995).
14. Lim, K. K. et al. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin. Proc. 71, 1182-1191 (1996).
15. Kupper, T. S. & Groves, R. W. The interleukin-1 axis and cutaneous inflammation. J. Invest. Dermatol. 105, 62S-66S (1995).
16. Murphy, J. E., Robert, C. & Kupper, T. S. Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J. Invest. Dermatol. 114, 602-608 (2000).
17. Heufler, C. et al. Interleukin 7 is produced by murine and human keratinocytes. J. Exp. Med. 178, 1109-1114 (1993).
18. Yang, D., Chertov, O. & Oppenheim, J. J. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defences and adaptive immunity. Cell. Mol. Life Sci. 58, 978-989 (2001).
19. Gallo, R. L., Murakami, M., Ohtake, T. & Zaiou, M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J. Allergy Clin. Immunol. 110, 823-831 (2002).
20. Kupper, T. S., Chua, A. O., Flood, P., McGuire, J. & Gubler, U. Interleukin 1 gene expression in cultured human keratinocytes is augmented by ultraviolet irradiation. J. Clin. Invest. 80, 430-436 (1987).
21. Wood, L. C., Elias, P. M. & Calhoun, C. Barrier disruption stimulates interleukin-1α expression and release from a preformed pool in murine epidermis. J. Invest. Dermatol. 106, 397-403 (1996).
22. Luger, T. A., Scholzen, T. & Grabbe, S. The role of α-melanocyte-stimulating hormone in cutaneous biology. J. Investig. Dermatol. Symp. Proc. 2, 87-93 (1997).
23. Dinarello, C. A. Interleukin-1, intereukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16, 457-499 (1998).
24. Fuhlbrigge, R. C. & Kupper, T. S. In Allergic Skin Disease (eds Leung, D. Y. M. & Greaves, M. W.) 29-52 (Marcel Dekker, New York, 2000).
25. Takashima, A. & Bergstresser, P. R. Cytokine-mediated communication by keratinocytes and Langerhans cells with dendritic epidermal T cells. Semin. Immunol. 8, 333-339 (1996).
26. Dahl, M. Clinical Immunodermatology (Mosby, St. Louis, 1996).
27. Stoll, S. et al. Production of IL-18 (IFN-γ-inducing factor) messenger RNA and functional protein by murine keratinocytes. J. Immunol. 159, 298-302 (1997).
28. Steinhoff, M., Brzoska, T. & Luger, T. A. Keratinocytes in epidermal immune responses. Curr. Opin. Allergy Clin. Immunol. 1, 469-476 (2001).
29. Kumar, S. et al. Identification and initial characterization of four novel members of the interleukin-1 family. J. Biol. Chem. 275, 10308-10314 (2000).
30. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
31. Sieling, P. A. & Modlin, R. L. Toll-like receptors: mammalian 'taste receptors' for a smorgasbord of microbial invaders. Curr. Opin. Microbiol. 5, 70-75 (2002).
32. Medzhitov, R. Toll-like receptors and innate immunity. Nature Rev. Immunol. 1, 135-145 (2001).
33. Barton, G. M. & Medzhitov, R. Control of adaptive immune responses by Toll-like receptors. Curr. Opin. Immunol. 14, 380-383 (2002).
34. Yang, R. B. et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 395, 284-288 (1998). This paper identified Toll-like receptor 2 (TLR2) as the receptor for lipopolysaccharide on mammalian cells, leading to an explosion of interest in TLRs as innate immune-response elements, as highlighted in references 35-40.
35. Brightbill, H. D. et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285, 732-736 (1999).
36. Aliprantis, A. O. et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285, 736-739 (1999).
37. Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103 (2001).
38. Tada, H. et al. Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor α by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol. Immunol. 46, 503-512 (2002).
39. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
40. Wagner, H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 5, 62-69 (2002).
41. Jarrossay, D., Napolitani, G., Colonna, M., Sallusto, F. & Lanzavecchia, A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 31, 3388-3393 (2001).
42. Kadowaki, N. et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863-869 (2001).
43. Krug, A. et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31, 3026-3037 (2001).
44. Medzhitov, R. & Janeway, C. A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91, 295-298 (1997).
45. Barnes, P. J. Nuclear factor-κB. Int. J. Biochem. Cell Biol. 29, 867-870 (1997).
46. von Andrian, U. H. & Mackay, C. R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343, 1020-1034 (2000).
47. Supajatura, V. et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity, J. Clin. Invest. 109, 1351-1359 (2002).
48. Marshall, J. S., McCurdy, J. D. & Olynych, T. Toll-like receptor-mediated activation of mast cells: implications for allergic disease? Int. Arch. Allergy Immunol. 132, 87-97 (2003).
49. McCurdy, J. D., Olynych, T. J., Maher, L. H. & Marshall, J. S. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 170, 1625-1629 (2003).
50. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702 (1992).
51. Lenz, A., Heine, M., Schuler, G. & Romani, N. Human and murine dermis contain dendritic cells. J. Clin. Invest. 92, 2587-2596 (1993).
52. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998). This review brings together the view of dendritic cells (DCs) as the central mediators between innate and adaptive immune responses.
53. Hart, D. N. J. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90, 3245-3287 (1997).
54. Pierre, P. et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388, 787-792 (1997).
55. Schuller, E. et al. In situ expression of the co-stimulatory molecules CD80 and CD86 on langerhans cells and inflammatory dendritic epidermal cells (IDEC) in atopic dermatitis. Arch. Dermatol. Res. 293, 448-454 (2001).
56. Wollenberg, A., Kraft, S., Hanau, D. & Bieber, T. Immunomorphological and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J. Invest. Dermatol. 106, 446-453 (1996).
57. Picker, L. J., Michie, S. A., Rott, L. S. & Butcher, E. C. A unique phenotype of skin-associated lymphocytes in human. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am. J. Pathol. 136, 1053-1068 (1990). This report provided the first evidence of a specific homing receptor for non-lymphoid tissues.
58. Pitzais, C. et al. Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum. 39, 137-145 (1996). This study, together with references 62 and 64, firmly established cutaneous lymphocyte antigen (CLA) as a specific marker of skin-homing T cells.
59. + T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin. Exp. Immunol. 126, 365-369 (2001).
60. Noorduyn, L. et al. Differential expression of the HECA-452 antigen (cutaneous lymphocyte associated antigen, CLA) in cutaneous and non-cutaneous T-cell lymphomas. Histopathology 21, 59-64 (1992).
61. Santamaria Babi, L. F., Perez Soler, M. T., Hauser, C. & Blaser, K. Skin-homing T cells in human cutaneous allergic inflammation. Immunol. Res. 14, 317-324 (1995).
62. Santamaria Babi, L. F. et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J. Exp. Med. 181, 1935-1940 (1995).
63. Tanaka, Y. et al. Distinct phenotype of leukemic T cells with various tissue tropisms. J. Immunol. 158, 3822-3829 (1997).
64. Davis, R. E. & Smoller, B. R. T lymphocytes expressing HECA-452 epitope are present in cutaneous acute graft-versus-host disease and erythema multiforme, but not in acute graft-versus-host disease in gut organs. Am. J. Pathol. 141, 691-698 (1992).
65. Rook, A. H. & Heald, P. The immunopathogenesis of cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am. 9, 997-1010 (1995).
66. 7 as the T-cell-homing receptor for Peyer's patches.
67. Mora, J. R. et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424, 88-93 (2003).
68. + T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J. Immunol, 172, 857-863 (2004). References 67 and 68 showed that T cells responding to DCs from different anatomic sites are induced to express different patterns of homing receptors.
69. + T cells specific for a skin-tropic virus. J. Clin. Invest. 110, 537-548 (2002).
70. + cytotoxic T cells to the skin and to the gut in response to infection with tissue-tropic viruses.
71. Armerding, D. & Kupper, T. S. Functional cutaneous lymphocyte antigen can be induced in essentially all peripheral blood T lymphocytes. Int. Arch. Allergy Immunol. 119, 212-222 (1999).
72. H2 cells. Eur. J. Immunol. 30, 3533-3541 (2000).
73. + T cells represent major subsets of human peripheral blood memory T cells migrating in response to CCL1/I-309. Eur. J. Immunol. 32, 3506-3514 (2002).
74. H2 memory cells to human skin in vivo. Eur. J. Immunol. 32, 3171-3180 (2002).
75. + skin homing T cells. J. Immunol. 169, 1189-1196 (2002).
76. Reiss, Y., Proudfoot, A. E., Power, C. A., Campbell, J. J. & Butcher, E. C. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med. 194, 1541-1547 (2001).
77. Morales, J. et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc. Natl. Acad. Sci. USA 96, 14470-14475 (1999).
78. Homey, B. et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nature Med. 8, 157-165 (2002).
79. Fitzhugh, D. J., Naik, S., Caughman, S. W. & Hwang, S. T. Cutting edge: C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro. J. Immunol. 165, 6677-6681 (2000).
80. Klunker, S. et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-γ-inducible protein 10, monokine induced by IFN-γ, and IFN-γ-inducible α-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J. Immunol. 171, 1078-1084 (2003).
81. Ferenczi, K., Fuhlbrigge, R. C., Pinkus, J., Pinkus, G. S. & Kupper, T. S. Increased CCR4 expression in cutaneous T cell lymphoma. Invest. Dermatol. 119, 1405-1410 (2002).
82. Kunkel, E. J. et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am. J. Pathol. 160, 347-355 (2002).
83. Janssen, G. H., Tangelder, G. J., Oude Egbrink, M. G. & Reneman, R. S. Spontaneous leukocyte rolling in venules in untraumatized skin of conscious and anesthetized animals. Am. J. Physiol. 267, H1199-H1204 (1994).
84. Robert, C. et al. Interaction of dendritic cells with skin endothelium: a new perspective on immunosurveillance. J. Exp. Med. 189, 627-636 (1999).
85. Chong, B. F., Murphy, J.-E., Kupper, T. S. & Fuhlbrigge, R. C. E-selectin, thymus- and activation-regulated chemokine/CCL17, and intercellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J. Immunol. 172, 1575-1581 (2004).
86. Weninger, W. et al. Specialized contributions by α (1,3)-fucosyltransferase-IV and FucT-VII during leukocyte rolling in dermal microvessels. Immunity 12, 665-676 (2000).
87. Groves, R. W. et al. Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin. J. Invest. Dermatol. 98, 384-387 (1992).
88. Langeveld-Wildschut, E. G. et al. Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. J. Allergy Clin. Immunol. 105, 1008-1016 (2000).
89. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999). This study distinguished effector memory T cells, which participate in peripheral inflammatory responses, from central memory T cells, which migrate through secondary lymphoid tissues and provide long-term memory.
90. Campbell, J. J. et al. CCR7 expression and memory T cell diversity in humans. J. Immunol. 166, 877-884 (2001).
91. Girolomoni, G., Sebastiani, S., Albanesi, C. & Cavani, A. T-cell subpopulations in the development of atopic and contact allergy. Curr. Opin. Immunol. 13, 733-737 (2001).
92. + regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J. Immunol. 171, 5760-5768 (2003).
93. + regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101, 4862-4869 (2003).
94. Wrone-Smith, T. & Nickoloff, B. J. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98, 1878-1887 (1996). This study firmly established that psoriasis is dependent on immune cells using an animal model of human skin grafted onto immune-deficient mice and injected with autologous T cells.
95. Kupper, T. S. Immunologic targets in psoriasis. N. Engl. J. Med. 349, 1987-1990 (2003).
96. Cather, J. & Menter, A. Novel therapies for psoriasis. Am. J. Clin. Dermatol. 3, 159-173 (2002).
97. Asadullah, K. et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin. Invest. 101, 783-794 (1998).
98. Trepicchio, W. L. et al. Interleukin-11 therapy selectively downregulates type 1 cytokine proinflammatory pathways in psoriasis lesions. J. Clin. Invest. 104, 1527-1537 (1999).
99. H2 responses and improves human autoimmune disease. Nature Med. 9, 40-46 (2003).
100. Cather, J. C. & Abramovits, W. Investigational therapies for psoriasis. J. Am. Acad. Dermatol. 49, S133-S138 (2003).
101. Williams, J. D. & Griffiths, C. E. Cytokine blocking agents in dermatology. Clin. Exp. Dermatol. 27, 585-590 (2002).
102. Bhushan, M. et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br. J. Dermatol. 146, 824-831 (2002).
103. Schon, M. P. et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nature Med. 8, 366-372 (2002).
104. Tofte, S. J. & Hanifin, J. M. Current management and therapy of atopic dermatitis. J. Am. Acad. Dermatol. 44, S13-S16 (2001).
105. Williams, H. C. Epidemiology of atopic dermatitis. Clin. Exp. Dermatol. 25, 522-529 (2000).
106. Hanifin, J. M. Epidemiology of atopic dermatitis. Monogr. Allergy 21, 116-131 (1987).
107. Engler, R. J., Kenner, J. & Leung, D. Y. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J. Allergy Clin. Immunol. 110, 357-365 (2002).
108. Sidbury, R. & Hanifin, J. M. Old, new, and emerging therapies for atopic dermatitis. Dermatol. Clin. 18, 1-11 (2000).
109. Shum, K. W., Lawton, S., Williams, H. C., Docherty, G. & Jones, J. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 2: audit of service process. Br. J. Dermatol. 142, 274-278 (2000).
110. Wuthrich, B. & Schmid-Grendelmeier, P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ('extrinsic') and the nonallergic ('intrinsic') AEDS. J. Investig. Allergol. Clin. Immunol. 13, 1-5 (2003).
111. Akdis, C. & Akdis, M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin. Exp. Allergy 33, 1618-1621 (2003).
112. H2 clones specific for seasonal and perennial allergens can be detected in blood and skin by their TCR-hypervariable regions. J. Immunol. 160, 2022-2027 (1998).
113. H2 cells in the immunopathogenesis of atopic dermatitis. Immunol. Today 19, 359-361 (1998).
114. Ong, P. Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151-1160 (2002).
115. Nomura, I. et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. 171, 3262-3269 (2003).
116. Grabbe, S. & Schwarz, T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Am. J. Contact Dermat. 7, 238-246 (1996).
117. Kimber, I. & Dearman, R. J. Allergic contact dermatitis: the cellular effectors. Contact Dermatitis 46, 1-5 (2002).
118. Leung, D. Y. Molecular basis of allergic diseases. Mol. Genet. Metab. 63, 157-167 (1998).
119. H1 immune responses. J. Invest. Dermatol. 114, 295-302 (2000).
120. Aractingi, S. & Chosidow, O. Cutaneous graft-versus-host disease. Arch. Dermatol. 134, 602-612 (1998).
121. Edelson, R. L. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann. NY Acad. Sci. 941, 1-11 (2001).
122. Rock, A. H. et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin. Exp. Immunol. 107 Suppl. 1, 16-20 (1997).
123. Yawalkar, N. et al. Profound loss of T cell receptor repertoire complexity in cutaneous T cell lymphoma. Blood 102, 4059-4066 (2003).
124. Kemp, E. H., Waterman, E. A. & Weetman, A. P. Immunological pathomechanisms in vitiligo. Expert Rev. Mol. Med. 3, 1-22 (2001).
125. Ogg, G. S., Dunbar, R., Romero, P., Chen, J. L. & Cerundolo, V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188, 1203-1208 (1998).
126. Clark, W. H., Jr, From, L., Bernardino, E. A. & Mihm, M. C. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 29, 705-727 (1969).
127. Ruiter, D. J., Bhan, A. K., Harrist, T. J., Sober, A. J. & Mihm, M. C., Jr. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J. Immunol. 129, 2808-2815 (1982).
128. Clark, W. H., Jr. et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol. 15, 1147-1165 (1984).
129. Ferradini, L. et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J. Clin. Invest. 91, 1183-1190 (1993).
130. Mackensen, A. et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 53, 3569-3573 (1993).
131. Mackensen, A. et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J. Clin. Invest. 93, 1397-1402 (1994).
132. Salvi, S. et al. Overexpression of the T-cell receptor β-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res. 55, 3374-3379 (1995).
133. Clark, W. H., Jr. et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81, 1893-1904 (1989).
134. Pastorfide, G. C. et al. Image analysis of stage 1 melanoma (1.00-2.50 mm): lymphocytic infiltrates related to metastasis and survival. J. Cutan. Pathol. 19, 390-397 (1992).
135. Clemente, C. G. et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303-1310 (1996).
136. Weber, L. W. et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA, J. Clin. Invest. 102, 1258-1264 (1998).
137. Bendandi, M. et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171-1177 (1999). This study highlighted the capacity of tumour-specific vaccination to induce complete remissions and set the standards for future cancer vaccine trials.
138. Restito, N. P. & Rosenberg, S. A. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol. 11, 50-57 (1999).
139. Nair, S. K. et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature Med. 6, 1011-1017 (2000).
140. Nestle, F. O., Banchereau, J. & Hart, D. Dendritic cells: on the move from bench to bedside. Nature Med. 7, 761-765 (2001).
141. Jager, E., Jager, D. & Knuth, A. Clinical cancer vaccine trials. Curr. Opin. Immunol. 14, 178-182 (2002).
142. Nestle, F. O. Vaccines and melanoma. Clin. Exp. Dermatol. 27, 597-601 (2002).
143. Dranoff, G. GM-CSF-secreting melanoma vaccines. Oncogene 22, 3188-3192 (2003).
144. Engleman, E. G. Dendritic cell-based cancer immunotherapy. Semin. Oncol. 30, 23-29 (2003).
145. + hematopoietic progenitor cells. Cancer Immunol. Immunother. 46, 118-122 (1999).
146. Onaitis, M., Kalady, M. F., Pruitt, S. & Tyler, D. S. Dendritic cell gene therapy. Surg. Oncol. Clin. N. Am. 11, 645-660 (2002).
147. Gilliet, M. et al. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood 102, 36-42 (2003).
148. Touloukian, C. E. & Rosenberg, S. A. A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute. Cancer J. Sci. Am. 5, 269-274 (1999).
149. Robert, C. et al. Gene therapy to target dendritic cells from blood to lymph nodes. Gene Ther. 10, 1479-1486 (2003).
150. + regulatory T cells in vivo in humans. Blood 100, 174-177 (2002).
151. Henderson, D. A. Smallpox: clinical and epidemiologic features. Med. Health R. I. 85, 107-108 (2002).
152. McClain, D. J. et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J. Infect. Dis. 175, 756-763 (1997). This report confirmed the decades old clinical impression that scarification as a method of vaccinia-virus vaccination was superior to subcutaneous and intramuscular injection in the induction of vaccinia-virus-specific immune responses.
153. Goldstein, J. A., Neff, J. M., Lane, J. M. & Koplan, J. P. Smallpox vaccination reactions, prophylaxis, and therapy of complications. Pediatrics 55, 342-347 (1975).
154. Leung, D. Y. & Soter, N. A. Cellular and immunologic mechanisms in atopic dermatitis. J. Am. Acad. Dermatol. 44, S1-S12 (2001).
155. Jackson, R. J. et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75, 1205-1210 (2001).
156. Ambach, A., Bonnekoh, B. & Gollnick, H. Perforin hyperreleasability and depletion in cytotoxic T cells from patients with exacerbated atopic dermatitis and asymptomatic minoconjunctivitis allergica. J. Allergy Clin. Immunol. 107, 878-886 (2001).
157. Hirata, T. et al. P-selectin glycoprotein ligand 1 (PSGL-1) is a physiological ligand for E-selectin in mediating T helper 1 lymphocyte migration. J. Exp. Med. 192, 1669-1676 (2000).
158. Abernathy-Carver, K., Sampson, H., Picker, L. & Leung, D. Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. J. Clin. Invest. 95, 913-918 (1995).
159. Tanaka, T. et al. Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC/Nga. Int. Arch. Allergy Immunol. 125, 236-240 (2001).
160. Girolomoni, G. & Pastore, S. The role of keratinocytes in the pathogenesis of atopic dermatitis. J. Am. Acad. Dermatol. 45, S25-S28 (2001).
161. Giustizieri, M. L. et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines, J. Allergy Clin. Immunol. 107, 871-877 (2001).
162. Pastore, S., Corinti, S., La Placa, M., Didona, B. & Girolomoni, G. Interferon-γ promotes exaggerated cytokine production in keratinocytes cultured from patients with atopic dermatitis. J. Allergy Clin. Immunol. 101, 538-544 (1998).